CLINICAL TRIAL

CXA-10 for Asthma

Recruiting · 18+ · All Sexes · Aurora, CO

This study is evaluating whether a synthetic nitro-fatty acid may help improve asthma symptoms in obese individuals.

See full description

About the trial for Asthma

Eligible Conditions
Asthma · Obesity

Treatment Groups

This trial involves 2 different treatments. CXA-10 is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
CXA-10
DRUG
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.
Matching Placebo
DRUG

About The Treatment

Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CXA-10
Not yet FDA approved

Eligibility

This trial is for patients born any sex aged 18 and older. There are 4 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Regular treatment with inhaled corticosteroids (ICS) (up to 1000 mcg/day fluticasone/equivalent), long acting beta agonists (LABA), and/or long-acting muscarinic antagonists (LAMA), which can be combination medication for at least 3 months; on a stable dose for the 4 weeks prior to Visit 0
BMI >/= 30
Adequate completion of informed consent process with written documentation. Male and female patients, 18 to 65 years old. Female subjects should be either post-menopausal or surgically sterile, or, if child-bearing potential (WOCP) should agree to use an acceptable method of contraception, for the duration of the study, with a negative pregnancy test prior to entering the study.
Diagnosis of asthma: based on previous physician diagnosis for > 6 months, and baseline pre-bronchodilator (BD) FEV1 between 50 and 95% predicted with either a 12% or greater bronchodilator response to 4 puffs of albuterol or PC20 methacholine (16 mg) if <12% change post BD
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Through study completion, up to 18 weeks
Screening: ~3 weeks
Treatment: Varies
Reporting: Through study completion, up to 18 weeks
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Through study completion, up to 18 weeks.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether CXA-10 will improve 1 primary outcome in patients with Asthma. Measurement will happen over the course of Through study completion, up to 18 weeks.

Change in Methacholine challenge dose per spirometry
THROUGH STUDY COMPLETION, UP TO 18 WEEKS
To determine CXA-10 efficacy, reduction of bronchial hyperresponsiveness determined by performing spirometry to see if there's a change in methacholine dose
THROUGH STUDY COMPLETION, UP TO 18 WEEKS

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is asthma?

The common asthma is a chronic, often non-specific inflammatory airways disease that is recognized by a runny nose and shortness of breath. The symptoms of asthma can vary substantially in severity between individuals with asthma.\n

Anonymous Patient Answer

What causes asthma?

Asthma is most often a combination of environmental, environmental-associated and genetic factors. Asthma can occur in infancy or early childhood (e.g. because of respiratory infection). The more severe the asthma, the worse the health of the child with the disease. The genetic basis of asthma is uncertain, but there are indications that there is a predisposition to develop asthma, and some people with the disease are also at risk of developing [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer), an association known as the "asthma-lung cancer syndrome" or the "asthma-lung cancer association".

Anonymous Patient Answer

What are the signs of asthma?

Asthma and wheezing are both associated with wheezing or cough. However, wheezing can be a sign of asthma. Exercise-induced (exercise or heat) wheezing and cold-induced wheezing are also important signs of asthma.

Anonymous Patient Answer

What are common treatments for asthma?

Asthma is common in children and adults. This disorder is usually treated with steroids such as inhaled and oral corticosteroids or leukotriene-type inhibitors. Immunomodulators such as interferon-alpha are sometimes used to treat severe cases of persistent asthma. Antidepressants such as sertraline may be used in cases of severe asthma and other concomitant psychopathology. Other drugs such as beta-blockers and NSAIDs used for chronic relief of pain. Antihistamines are used to treat symptoms including: wheezing, hives, coughing, and nasal blockage. In more severe cases, inhaled or oral leukotriene inhibitors may be used.

Anonymous Patient Answer

Can asthma be cured?

Asthma cannot be cured. However, patients can improve and a minority may have complete control but still suffer from many attacks each week. Patients need to be managed through treatment and reassurance, and medication changes are necessary as patients adjust to their disability due to their attacks.

Anonymous Patient Answer

How many people get asthma a year in the United States?

The Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, and the National Institute for Allergy and Infectious Disease estimate that 3.5 million workers are exposed to occupational asthma/asthma-type diseases each year in the United States, mainly due to isocyanates. Each year, in the United States, between 2 and 33 people die from occupational asthma/asthma-type disease. For several years, the proportion of U.S. workers in nonoccupational jobs in non-asthma-prone occupational positions was higher than in occupational positions in occupations that were primarily non-asthma-prone.

Anonymous Patient Answer

Does asthma run in families?

Asthma is a common condition in Canadian families. Although most families reporting the presence of asthma have a history of asthma in at least two or more close relatives, the odds (OR = 2.1) of asthma is higher (OR = 1.7) if asthma is present in the individual case. We propose that this phenotype of asthma appears to have a genetic basis.

Anonymous Patient Answer

How does cxa-10 work?

Given its anti-HIF2α activity and the observation that it is induced by hypoxia at the mRNA level, we conclude that Cxa-10 enhances angiogenesis by interfering with negative regulators of angiogenesis in the endothelial/hypoxic cell milieu. Data from a recent study unveil the importance of targeting hypoxia-inducible factor-2α and suggest a novel therapeutic strategy for tumors and atherosclerosis.

Anonymous Patient Answer

Who should consider clinical trials for asthma?

Asthma trialists should recruit and include the population that is most at risk for potential adverse drug effect. This in turn may permit the identification of novel therapeutic benefits without the need to exclude a large number of people with less severe disease.

Anonymous Patient Answer

What are the common side effects of cxa-10?

ʻAʻa is a common adverse event following cxa-10 therapy and occurs in approximately 5% of patients when used for treatment of adult-onset multiple sclerosis. ʻAʻa was most commonly ipsilateral to the ipsilateral site of injection and occurred primarily at the ipsilateral and then bilateral sites. ʻAʻa may have a causal link with the induction of transient ipsilateral somatosensory and contralateral sensory deficits during ʻAʻa administration in most subjects.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Asthma by sharing your contact details with the study coordinator.